Patents by Inventor Xiongyu Wu

Xiongyu Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW DERIVATES OF DHAA WITH ELECTROSTATIC TUNING
    Publication number: 20200239412
    Abstract: Dehydroabietic acid derivatives according to Formula Ia or Formula Ib and all stereoisomers thereof, having a linker chain A of 1 to 10 atoms selected from carbon, nitrogen and oxygen to a group X capable of being negatively charged at a physiological pH and covalently attached to the linker chain A, selected from carboxyl, sulfate, sulfonate and phosphate groups.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 30, 2020
    Inventors: Fredrik ELINDER, Xiongyu WU, Nina OTTOSSON, Peter KONRADSSON, Malin SILVERÅ EJNEBY
  • Substituted pyrazoles as estrogen receptor ligands
    Patent number: 8921402
    Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 30, 2014
    Assignee: Karo Bio AB
    Inventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
  • SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS
    Publication number: 20140128435
    Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: KARO BIO AB
    Inventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
  • Substituted pyrazoles as estrogen receptor ligands
    Patent number: 8653112
    Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: February 18, 2014
    Assignee: Karo Bio AB
    Inventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
  • SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS
    Publication number: 20120202853
    Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Application
    Filed: October 6, 2010
    Publication date: August 9, 2012
    Applicant: KARO BIO AB
    Inventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
  • Tricyclic angiotensin II agonists
    Patent number: 8080571
    Abstract: There is provided compounds of formula I, wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: December 20, 2011
    Assignee: Vicore Pharma AB
    Inventors: Mathias Alterman, Anders Hallberg, Xiongyu Wu
  • Tricyclic angiotensin II agonists
    Patent number: 8067418
    Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: November 29, 2011
    Assignee: Vicore Pharma AB
    Inventors: Mathias Alterman, Anders Hallberg, Xiongyu Wu
  • NOVEL ESTROGEN RECEPTOR LIGANDS
    Publication number: 20100210524
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Application
    Filed: July 21, 2008
    Publication date: August 19, 2010
    Inventors: Theresa Apelqvist, Joakim Löfstedt, Thomas Norin, Mattias Wennerstål, Xiongyu Wu, Lars Hagberg
  • Tricyclic Angiotensin II Agonists
    Publication number: 20090215847
    Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 27, 2009
    Inventors: Mathias Alterman, Anders Hallberg, Xiongyu Wu
  • Tricyclic Angiotensin II Agonists
    Publication number: 20090042931
    Abstract: There is provided compounds of formula I, wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Application
    Filed: April 12, 2006
    Publication date: February 12, 2009
    Applicant: Vicore Pharma AB
    Inventors: Mathias Alterman, Anders Hallberg, Xiongyu Wu